Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 4, 2000

View Archived Issues

Researchers solve structure of cathepsin V, a cancer-associated protease

Genzyme General and CAT to jointly develop anti-TGF-beta antibodies

Ribozyme presents HBV data, announces formal HBV development program

InterMune to commence Actimmune clinical trial in ovarian cancer

Copernicus receives grant for PLASmin Complex project

Neurobiological Technologies reviews fourth quarter developments

First European endostatin study begins

Pfizer submits IND for human monoclonal antibody developed with Abgenix

PowderJect completes acquisition of Medeva vaccines

Initial phase I study of AC-3056 completed by Amylin

Orphan Medical submits Xyrem NDA for narcolepsy symptoms

FDA approves cream formulation of Allergan's Tazorac

BLA supplement filed for alteplase

Antibodies for cancer therapy disclosed in recent patent by Genentech

Takeda describes compounds which enhance bone formation

Novel GH secretagogues emerge from Japanese/U.S. R&D collaboration

Fujisawa patents pyridine-based NOS inhibitors

Bicyclic compounds and their use in inflammation reported in Aventis patent

Japanese lab presents new inhibitors of TNF production

New series from Senju particularly useful for ocular disorders

Schering scientists disclose new antitumor epothilone derivatives

Excellent efficacy and safety profile of novel antifungal agent confirmed in clinical trials

Versicor presents interim clinical findings on its second-generation glycopeptide antibiotic

Selectin inhibitor OC-229-648 chosen for further evaluation in COPD and asthma

Inspire submits IND for new cystic fibrosis treatment

Novel IL-5 biosynthesis inhibitor R-146225 profiled at recent inflammation meeting

Dong-A reports preclinical data on new pyridine-containing oxazolidinones

First fusion inhibitor enters phase III for AIDS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...